1. In Vivo
  2. >>Business Strategy

Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition

 
• By Joseph Haas

BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

Boehringer Ingelheim headquarters in Ingelheim, Germany
BI's R&D strategy centers on novel targets and breakthrough therapies for unmet needs • Source: Boehringer Ingelheim (dieth+schröder-fotografie)

Like many of its large pharma peers, Boehringer Ingelheim GmbH likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeutic modalities, target discovery and validation, and ways to hit those targets. The German firm sets high standards for best- and/or first-in-class pipeline assets and breakthrough therapy designations.

But as a privately held and mostly family-owned pharmaceutical company, BI has advantages over its peers in terms of being...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By Ashley Yeo

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By David Wild

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

More from In Vivo

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By David Wild

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.